Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
44.8M
-
Number of holders
-
687
-
Total 13F shares, excl. options
-
40.9M
-
Shares change
-
-2.97M
-
Total reported value, excl. options
-
$17.1B
-
Value change
-
-$1.06B
-
Put/Call ratio
-
2.1
-
Number of buys
-
309
-
Number of sells
-
-343
-
Price
-
$419.21
Significant Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR) as of Q3 2025
796 filings reported holding UTHR - UNITED THERAPEUTICS Corp - Common Stock as of Q3 2025.
UNITED THERAPEUTICS Corp - Common Stock (UTHR) has 687 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.9M shares
of 44.8M outstanding shares and own 91.2% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (5.35M shares), VANGUARD GROUP INC (4.42M shares), RENAISSANCE TECHNOLOGIES LLC (2.17M shares), Avoro Capital Advisors LLC (2.02M shares), STATE STREET CORP (1.92M shares), WELLINGTON MANAGEMENT GROUP LLP (1.4M shares), GEODE CAPITAL MANAGEMENT, LLC (1.25M shares), AQR CAPITAL MANAGEMENT LLC (986K shares), Darwin Global Management, Ltd. (749K shares), and LSV ASSET MANAGEMENT (687K shares).
This table shows the top 687 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.